ArticleMolecular diversity2026
Targeting histidine biosynthesis in Acinetobacter baumannii: structure-based discovery of natural inhibitors of ATP-phosphoribosyltransferase.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Review
- Repurposing bleomycin against Acinetobacter baumannii HisG: computational, biophysical, and antibacterial evidence.Journal of computer-aided molecular design · 2026Article
- Virtual screening and molecular dynamics analysis of Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) inhibitors targeting pyrimidine biosynthesis pathway.Folia microbiologica · 2026Article
- Computational identification and multi-level validation of marine fungal metabolites as potent inhibitors of Acinetobacter baumannii GuaB.Folia microbiologica · 2026Article
- Antibacterial and antibiofilm efficacy of ar-turmerone derived from Curcuma longa L. arrested multidrug-resistant pathogenic Gram-positive bacteria.Archives of microbiology · 2025Article
- Asperuloside: an emerging therapeutic candidate for Parkinson's disease through molecular mechanistic insights.Inflammopharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The increasing threat of multidrug-resistant Acinetobacter baumannii infections demands the development of novel antimicrobials targeting unexplored bacterial pathways. ATP phosphoribosyltransferase (ATP-PRT), the first and rate-limiting enzyme in the bacterial histidine biosynthesis pathway, represents an excellent therapeutic target since it doesn't exist in the mammalian system and thus ensures excellent selectivity towards pathogenic bacteria. This study utilized a systematic computational-experimental methodology to identify natural inhibitors of the ATP-PRT enzyme. It utilized an all-inclusive structure-based virtual screening against ~ 20,000 natural compounds through the use of hierarchical docking methods to account for receptor flexibility. In order to evaluate complex stability under physiological conditions, top hits were further validated using 100 ns molecular dynamics simulations. Two natural molecules, Pentagalloylglucose (PGG) and Punicalagin, emerged as effective lead compounds with docking scores of -7.813 and -7.626 kcal/mol, respectively. Binding analysis of both compounds showed strong interaction with conserved active site residues (Arg29, Asp91, Glu160, Asp176, Thr177, and Thr180). In-vitro broth microdilution assays confirmed potent antimicrobial activity, with minimum inhibitory concentrations (MICs) of 7.82 µg/mL for both compounds against multidrug-resistant A. baumannii. Time-kill kinetics demonstrated concentration-dependent bactericidal action, with > 95% bacterial reduction within 12 h at MIC, indicating rapid antimicrobial onset. Intracellular histidine quantification further verified pathway inhibition in PGG- and Punicalagin-treated cells compared to controls. Surface plasmon resonance (SPR) analysis confirmed direct binding to ATP-PRT, with equilibrium dissociation constants (KD) of 7.7 nM for PGG and 7.2 µM for Punicalagin. Collectively, these findings highlight the therapeutic potential of PGG and Punicalagin as natural ATP-PRT inhibitors, effectively targeting histidine biosynthesis in A. baumannii.
Indexed as
Identifiers
41231374What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.